Frontline and Relapsed Rhabdomyosarcoma (FAR-RMS) Clinical Trial: A Report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG)

Julia Chisholm; Henry Mandeville; Madeleine Adams; Veronique Minard-Collin; Timothy Rogers; Anna Kelsey; Janet Shipley; Rick R. van Rijn; Isabelle de Vries; Roelof van Ewijk; Bart de Keizer; Susanne A. Gatz; Michela Casanova; Lisa Lyngsie Hjalgrim; Charlotte Firth; Keith Wheatley; Pamela Kearns; Wenyu Liu; Amanda Kirkham; Helen Rees; Gianni Bisogno; Ajla Wasti; Sara Wakeling; Delphine Heenen; Deborah A. Tweddle; Johannes H. M. Merks; Meriel Jenney; Dominique Heymann

doi:10.3390/cancers16050998

Frontline and Relapsed Rhabdomyosarcoma (FAR-RMS) Clinical Trial: A Report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG)

Julia Chisholm^*, Henry Mandeville, Madeleine Adams, Veronique Minard-Collin, Timothy Rogers, Anna Kelsey, Janet Shipley, Rick R. van Rijn, Isabelle de Vries, Roelof van Ewijk, Bart de Keizer, Susanne A. Gatz, Michela Casanova, Lisa Lyngsie Hjalgrim, Charlotte Firth, Keith Wheatley, Pamela Kearns, Wenyu Liu, Amanda Kirkham, Helen ReesGianni Bisogno, Ajla Wasti, Sara Wakeling, Delphine Heenen, Deborah A. Tweddle, Johannes H. M. Merks, Meriel Jenney, Dominique Heymann (Editor)

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

96 Downloads (Pure)

Abstract

Simple Summary: This article summarises the international Frontline and Relapsed Rhabdomyosarcoma (FaR-RMS) clinical trial for patients with rhabdomyosarcoma. The trial has multiple research questions relating to chemotherapy and radiotherapy and biological and imaging studies as well as to the introduction of novel drugs for patients with very high-risk disease. The rationale, background, and international collaboration of the trial are explained, and how the data will be used to inform future studies is outlined. Abstract: The Frontline and Relapsed Rhabdomyosarcoma (FaR-RMS) clinical trial is an overarching, multinational study for children and adults with rhabdomyosarcoma (RMS). The trial, developed by the European Soft Tissue Sarcoma Study Group (EpSSG), incorporates multiple different research questions within a multistage design with a focus on (i) novel regimens for poor prognostic subgroups, (ii) optimal duration of maintenance chemotherapy, and (iii) optimal use of radiotherapy for local control and widespread metastatic disease. Additional sub-studies focusing on biological risk stratification, use of imaging modalities, including [18F]FDG PET-CT and diffusion-weighted MRI imaging (DWI) as prognostic markers, and impact of therapy on quality of life are described. This paper forms part of a Special Issue on rhabdomyosarcoma and outlines the study background, rationale for randomisations and sub-studies, design, and plans for utilisation and dissemination of results.

Original language	English
Article number	998
Number of pages	23
Journal	Cancers
Volume	16
Issue number	5
Early online date	29 Feb 2024
DOIs	https://doi.org/10.3390/cancers16050998
Publication status	E-pub ahead of print - 29 Feb 2024

Bibliographical note

Funding
This study is funded by Cancer Research UK, grant number CRUK/17/011. The regorafenib arm of the FaR-RMS relapse study is funded by the pharmaceutical company Bayer. The Bayer specific code is 17529. The biological studies have been funded by Alice’s Arc Charity.

Keywords

radiotherapy
clinical trial
FaR-RMS
EpSSG
novel agents
randomisation
chemotherapy
rhabdomyosarcoma

Access to Document

10.3390/cancers16050998Licence: Creative Commons: Attribution (CC BY)

ChisholmJ2024Frontline.pdfFinal published version, 1.25 MBLicence: Creative Commons: Attribution (CC BY)

1 Comment/debate

Correction: Chisholm et al. Frontline and Relapsed Rhabdomyosarcoma (FaR-RMS) Clinical Trial: A Report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG). Cancers 2024, 16, 998
Chisholm, J., Mandeville, H., Adams, M., Minard-Collin, V., Rogers, T., Kelsey, A., Shipley, J., van Rijn, R. R., de Vries, I., van Ewijk, R., de Keizer, B., Gatz, S. A., Casanova, M., Hjalgrim, L. L., Firth, C., Wheatley, K., Kearns, P., Liu, W., Kirkham, A. & Rees, H. & 7 others, Bisogno, G., Wasti, A., Wakeling, S., Heenen, D., Tweddle, D. A., Merks, J. H. M. & Jenney, M., 9 Oct 2024, In: Cancers. 16, 19, 2 p., 3427.
Research output: Contribution to journal › Comment/debate › peer-review

Open Access
File

6 Downloads (Pure)

1 Active

CRUK/17/011 FaR-RMS: A multiarm-multistage study for children and adults with localised and metastatic frontline and relapsed RhabdoMyoSarcoma.
Kearns, P. (Co-Investigator), Gatz, S. (Principal Investigator), Liu, W. (Researcher), Gaunt, P. (Researcher), Jackson, A. (Researcher) & Pirrie, S. (Researcher)
Cancer Research Uk, SIOP Europe
1/02/18 → 31/01/28
Project: Research

Cite this

Chisholm, J., Mandeville, H., Adams, M., Minard-Collin, V., Rogers, T., Kelsey, A., Shipley, J., van Rijn, R. R., de Vries, I., van Ewijk, R., de Keizer, B., Gatz, S. A., Casanova, M., Hjalgrim, L. L., Firth, C., Wheatley, K., Kearns, P., Liu, W., Kirkham, A., ... Heymann, D. (Ed.) (2024). Frontline and Relapsed Rhabdomyosarcoma (FAR-RMS) Clinical Trial: A Report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG). Cancers, 16(5), Article 998. Advance online publication. https://doi.org/10.3390/cancers16050998

@article{3095149ed4fe45009878b5c9383050b1,

title = "Frontline and Relapsed Rhabdomyosarcoma (FAR-RMS) Clinical Trial: A Report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG)",

abstract = "Simple Summary: This article summarises the international Frontline and Relapsed Rhabdomyosarcoma (FaR-RMS) clinical trial for patients with rhabdomyosarcoma. The trial has multiple research questions relating to chemotherapy and radiotherapy and biological and imaging studies as well as to the introduction of novel drugs for patients with very high-risk disease. The rationale, background, and international collaboration of the trial are explained, and how the data will be used to inform future studies is outlined. Abstract: The Frontline and Relapsed Rhabdomyosarcoma (FaR-RMS) clinical trial is an overarching, multinational study for children and adults with rhabdomyosarcoma (RMS). The trial, developed by the European Soft Tissue Sarcoma Study Group (EpSSG), incorporates multiple different research questions within a multistage design with a focus on (i) novel regimens for poor prognostic subgroups, (ii) optimal duration of maintenance chemotherapy, and (iii) optimal use of radiotherapy for local control and widespread metastatic disease. Additional sub-studies focusing on biological risk stratification, use of imaging modalities, including [18F]FDG PET-CT and diffusion-weighted MRI imaging (DWI) as prognostic markers, and impact of therapy on quality of life are described. This paper forms part of a Special Issue on rhabdomyosarcoma and outlines the study background, rationale for randomisations and sub-studies, design, and plans for utilisation and dissemination of results.",

keywords = "radiotherapy, clinical trial, FaR-RMS, EpSSG, novel agents, randomisation, chemotherapy, rhabdomyosarcoma",

author = "Julia Chisholm and Henry Mandeville and Madeleine Adams and Veronique Minard-Collin and Timothy Rogers and Anna Kelsey and Janet Shipley and {van Rijn}, {Rick R.} and {de Vries}, Isabelle and {van Ewijk}, Roelof and {de Keizer}, Bart and Gatz, {Susanne A.} and Michela Casanova and Hjalgrim, {Lisa Lyngsie} and Charlotte Firth and Keith Wheatley and Pamela Kearns and Wenyu Liu and Amanda Kirkham and Helen Rees and Gianni Bisogno and Ajla Wasti and Sara Wakeling and Delphine Heenen and Tweddle, {Deborah A.} and Merks, {Johannes H. M.} and Meriel Jenney and Dominique Heymann",

note = "Funding This study is funded by Cancer Research UK, grant number CRUK/17/011. The regorafenib arm of the FaR-RMS relapse study is funded by the pharmaceutical company Bayer. The Bayer specific code is 17529. The biological studies have been funded by Alice{\textquoteright}s Arc Charity.",

year = "2024",

month = feb,

day = "29",

doi = "10.3390/cancers16050998",

language = "English",

volume = "16",

journal = "Cancers",

issn = "2072-6694",

publisher = "MDPI",

number = "5",

}

Chisholm, J, Mandeville, H, Adams, M, Minard-Collin, V, Rogers, T, Kelsey, A, Shipley, J, van Rijn, RR, de Vries, I, van Ewijk, R, de Keizer, B, Gatz, SA, Casanova, M, Hjalgrim, LL, Firth, C , Wheatley, K , Kearns, P, Liu, W, Kirkham, A, Rees, H, Bisogno, G, Wasti, A, Wakeling, S, Heenen, D, Tweddle, DA, Merks, JHM, Jenney, M & Heymann, D (ed.) 2024, 'Frontline and Relapsed Rhabdomyosarcoma (FAR-RMS) Clinical Trial: A Report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG)', Cancers, vol. 16, no. 5, 998. https://doi.org/10.3390/cancers16050998

TY - JOUR

T1 - Frontline and Relapsed Rhabdomyosarcoma (FAR-RMS) Clinical Trial: A Report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG)

AU - Chisholm, Julia

AU - Mandeville, Henry

AU - Adams, Madeleine

AU - Minard-Collin, Veronique

AU - Rogers, Timothy

AU - Kelsey, Anna

AU - Shipley, Janet

AU - van Rijn, Rick R.

AU - de Vries, Isabelle

AU - van Ewijk, Roelof

AU - de Keizer, Bart

AU - Gatz, Susanne A.

AU - Casanova, Michela

AU - Hjalgrim, Lisa Lyngsie

AU - Firth, Charlotte

AU - Wheatley, Keith

AU - Kearns, Pamela

AU - Liu, Wenyu

AU - Kirkham, Amanda

AU - Rees, Helen

AU - Bisogno, Gianni

AU - Wasti, Ajla

AU - Wakeling, Sara

AU - Heenen, Delphine

AU - Tweddle, Deborah A.

AU - Merks, Johannes H. M.

AU - Jenney, Meriel

A2 - Heymann, Dominique

N1 - Funding This study is funded by Cancer Research UK, grant number CRUK/17/011. The regorafenib arm of the FaR-RMS relapse study is funded by the pharmaceutical company Bayer. The Bayer specific code is 17529. The biological studies have been funded by Alice’s Arc Charity.

PY - 2024/2/29

Y1 - 2024/2/29

N2 - Simple Summary: This article summarises the international Frontline and Relapsed Rhabdomyosarcoma (FaR-RMS) clinical trial for patients with rhabdomyosarcoma. The trial has multiple research questions relating to chemotherapy and radiotherapy and biological and imaging studies as well as to the introduction of novel drugs for patients with very high-risk disease. The rationale, background, and international collaboration of the trial are explained, and how the data will be used to inform future studies is outlined. Abstract: The Frontline and Relapsed Rhabdomyosarcoma (FaR-RMS) clinical trial is an overarching, multinational study for children and adults with rhabdomyosarcoma (RMS). The trial, developed by the European Soft Tissue Sarcoma Study Group (EpSSG), incorporates multiple different research questions within a multistage design with a focus on (i) novel regimens for poor prognostic subgroups, (ii) optimal duration of maintenance chemotherapy, and (iii) optimal use of radiotherapy for local control and widespread metastatic disease. Additional sub-studies focusing on biological risk stratification, use of imaging modalities, including [18F]FDG PET-CT and diffusion-weighted MRI imaging (DWI) as prognostic markers, and impact of therapy on quality of life are described. This paper forms part of a Special Issue on rhabdomyosarcoma and outlines the study background, rationale for randomisations and sub-studies, design, and plans for utilisation and dissemination of results.

AB - Simple Summary: This article summarises the international Frontline and Relapsed Rhabdomyosarcoma (FaR-RMS) clinical trial for patients with rhabdomyosarcoma. The trial has multiple research questions relating to chemotherapy and radiotherapy and biological and imaging studies as well as to the introduction of novel drugs for patients with very high-risk disease. The rationale, background, and international collaboration of the trial are explained, and how the data will be used to inform future studies is outlined. Abstract: The Frontline and Relapsed Rhabdomyosarcoma (FaR-RMS) clinical trial is an overarching, multinational study for children and adults with rhabdomyosarcoma (RMS). The trial, developed by the European Soft Tissue Sarcoma Study Group (EpSSG), incorporates multiple different research questions within a multistage design with a focus on (i) novel regimens for poor prognostic subgroups, (ii) optimal duration of maintenance chemotherapy, and (iii) optimal use of radiotherapy for local control and widespread metastatic disease. Additional sub-studies focusing on biological risk stratification, use of imaging modalities, including [18F]FDG PET-CT and diffusion-weighted MRI imaging (DWI) as prognostic markers, and impact of therapy on quality of life are described. This paper forms part of a Special Issue on rhabdomyosarcoma and outlines the study background, rationale for randomisations and sub-studies, design, and plans for utilisation and dissemination of results.

KW - radiotherapy

KW - clinical trial

KW - FaR-RMS

KW - EpSSG

KW - novel agents

KW - randomisation

KW - chemotherapy

KW - rhabdomyosarcoma

U2 - 10.3390/cancers16050998

DO - 10.3390/cancers16050998

M3 - Article

SN - 2072-6694

VL - 16

JO - Cancers

JF - Cancers

IS - 5

M1 - 998

ER -

Frontline and Relapsed Rhabdomyosarcoma (FAR-RMS) Clinical Trial: A Report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG)

Abstract

Bibliographical note

Keywords

Access to Document

Fingerprint

Research output

Correction: Chisholm et al. Frontline and Relapsed Rhabdomyosarcoma (FaR-RMS) Clinical Trial: A Report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG). Cancers 2024, 16, 998

Projects

CRUK/17/011 FaR-RMS: A multiarm-multistage study for children and adults with localised and metastatic frontline and relapsed RhabdoMyoSarcoma.

Cite this